Eagle Pharmaceuticals (NASDAQ:EGRX) had its target price dropped by equities research analysts at Cantor Fitzgerald from $81.00 to $80.00 in a research note issued on Thursday, September 20th. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 33.02% from the company’s previous close.
A number of other analysts have also issued reports on the stock. Royal Bank of Canada set a $84.00 target price on shares of Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Mizuho upgraded shares of Eagle Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research report on Monday, June 11th. Zacks Investment Research lowered shares of Eagle Pharmaceuticals from a “strong-buy” rating to a “sell” rating in a research report on Tuesday, September 18th. Piper Jaffray Companies set a $88.00 target price on shares of Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 7th. Finally, raised their target price on shares of Eagle Pharmaceuticals to $119.00 and gave the stock a “buy” rating in a research report on Tuesday, July 3rd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Eagle Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $86.50.
Shares of EGRX traded up $0.16 during mid-day trading on Thursday, reaching $60.14. 233,104 shares of the company’s stock were exchanged, compared to its average volume of 235,428. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.22 and a quick ratio of 4.09. Eagle Pharmaceuticals has a 52-week low of $48.84 and a 52-week high of $85.66. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of 17.85 and a beta of 1.32.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.80 by $0.15. Eagle Pharmaceuticals had a net margin of 13.81% and a return on equity of 19.71%. The business had revenue of $59.30 million during the quarter, compared to analysts’ expectations of $51.78 million. On average, equities analysts expect that Eagle Pharmaceuticals will post 2.15 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Itau Unibanco Holding S.A. acquired a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at $108,000. Macquarie Group Ltd. boosted its holdings in shares of Eagle Pharmaceuticals by 400.0% in the 2nd quarter. Macquarie Group Ltd. now owns 1,500 shares of the specialty pharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,200 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in shares of Eagle Pharmaceuticals by 232.6% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,866 shares of the specialty pharmaceutical company’s stock valued at $141,000 after purchasing an additional 1,305 shares during the last quarter. Piedmont Investment Advisors LLC acquired a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at $150,000. Finally, California Public Employees Retirement System acquired a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at $208,000.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Featured Story: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.